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Abstract The central nervous system (CNS) is traditionally
viewed as an immune privileged site in which overzealous
immune cells are prevented from doing irreparable damage.
It was believed that immune responses occurring within the
CNS could potentially do more damage than the initial
pathogenic insult itself. However, virtually every aspect of
CNS tissue damage, including degeneration, tumors, infec-
tion, and of course autoimmunity, involves a significant
cellular inflammatory component. While the blood–brain
barrier (BBB) inhibits diffusion of hydrophilic (immune)
molecules across brain capillaries, activated lymphocytes
readily pass the endothelial layer of postcapillary venules
without difficulty. In classic neuro-immune diseases such as
multiple sclerosis or acute disseminated encephalomyelitis,
it is thought that neuroantigen-reactive lymphocytes, which
have escaped immune tolerance, now invade the CNS and
are responsible for tissue damage, demyelination, and axo-
nal degeneration. The developed animal model for these
disorders, experimental autoimmune encephalomyelitis
(EAE), reflects many aspects of the human conditions.
Studies in EAE proved that auto-reactive encephalitogenic T
helper (Th) cells are responsible for the onset of the disease.
Th cells recognize their cognate antigen (Ag) only when
presented by professional Ag-presenting cells in the context
of major histocompatibility complex class II molecules. The
apparent target structures of EAE immunity are myelinating
oligodendrocytes, which are not capable of presenting Ag to
invading encephalitogenic T cells. A compulsory third party
is thus required to mediate between the attacking T cells and
the myelin-expressing target. This review will discuss the
recent advances in this field of research and we will discuss
the journey of an auto-reactive T cell from its site of
activation into perivascular spaces and further into the target
tissue.
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Introduction
The central nervous system (CNS) is often referred to as a
site of limited immune surveillance. This concept dates
back to the seminal work of Medawar [1] and Barker and
Billingham demonstrating that allografts fare better in the
CNS compared to other tissues [2, 3]. Its “immunologically
privileged” status has for long been attributed to the blood–
brain barrier (BBB) and the lack of classic lymph vessels.
However, the concept of a BBB describes a mechanical
diffusion barrier for hydrophilic molecules (including
plasma proteins such as antibodies and complement)
formed by specialized endothelial cells at the level of
capillaries, while recruitment of leukocytes takes place in
postcapillary venules. In fact, it became apparent that
leukocytes readily cross the brain endothelial cells to reside
in perivascular spaces or move on into the neuropil (for a
review, see [4, 5]. Moreover, it is now established that
antigens efficiently drain into cervical lymph nodes via the
cribroid plate and perineural sheath of cranial nerves [6],
and recent data suggest similar routes for antigen-pre-
senting cells [7–9]. In fact, the CNS is the apparent target of
heavily studied autoimmune diseases such as multiple
sclerosis (MS), acute disseminated encephalomyelitis
(ADEM), and its animal model experimental autoimmune
encephalomyelitis (EAE). Although the etiology of MS
remains to be definitively established, the most widely
accepted view of the pathogenesis of the disease implicates
a cellular immune response as a central requirement
(reviewed in [10]). This view is supported by the
histopathologic observations of the presence of activated
T cells in the perivascular spaces and the parenchyma in the
early phases of the disease. These inflammatory lesions are
the apparent substrates corresponding to the recurrent
lesions seen with magnetic resonance imaging [11–13].
Studies of the EAE model have helped define the
sequence of events involved in the development of
autoimmune CNS-directed inflammatory disease. This
sequence of immunopathological events can be subdivided
into two major phases:
1. Initial T-cell priming/activation
2. Subsequent recruitment and effector phase
T-cell priming can be initiated by systemic immunization
with myelin Ags [10]. Protein Ag and peptides are
presented by Ag-presenting cells (APCs) within secondary
lymphoid organs leading to the activation and expansion of
neuroantigen-reactive T cells. The major antigens that can
induce EAE include myelin basic protein (MBP), proteo-
lipid protein, and myelin oligodendrocyte glycoprotein
(MOG). Activated myelin-reactive T cells migrate then to
the CNS where they reencounter their cognate Ag, in the
context of major histocompatibility complex (MHC) class
II molecules [14, 15]. Within the CNS, initial Ag
presentation is likely to occur in Virchow–Robin spaces
(Fig. 1). Perivascular macrophages (MΦs)/“microglia” as
well as dendritic cells (DCs) located within this compart-
ment [16, 17] are the only cells associated with the CNS
expressing MHC class II molecules. The contribution of
astroglia in Ag presentation during the early phase of
disease is unlikely (reviewed in [18]). It is widely held that
the activation and expansion of encephalitogenic T cells
occurs within the systemic immune compartment and not
within the CNS. This is certainly the case for EAE and
ADEM and we will thus, in this review, not elaborate on T-
cell priming during immunization-induced autoimmunity.
We will, however, later discuss the hypothesis that CNS
inflammation may be initiated within the CNS.
Fig. 1 Topography of the perivascular (Virchow–Robin spaces).
a Three basal laminae separate the blood from the neuropil. The first
one (1) is located around the endothelium. At regions where
pericytes engulf these cells, the lamina splits and forms a second
sheath (2). The third membrane (3) is associated with the astrocytic
endfeet building the glia limitans (labeled with GFAP and indicated
by arrows). The compartment between the second and the third
basement membrane is the perivascular space. Note that pericytes
(PY) and perivascular antigen-presenting cells (PC, a macrophage is
shown here) belong to different compartments. Open arrows
indicate cellular processes of the macrophage in vicinity to the
vessel wall. b, c The Virchow–Robin space is connected to the
subarachnoid space as evidenced by intraventricular tracer injec-
tions. At this point, a dextran-amine (mini-ruby, MR) was inserted.
Within minutes, the tracer diffuses within the CSF along the
perivascular spaces, where it is phagocytosed by perivascular cells
(arrow in b) leading to phagocytosis-dependent labeling. The tracer
remains confined to the compartment between the second and third
basal lamina. The glia limitans apparently provides a tight barrier
(c) [118]. Scale bars, 0.5 μm
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After a few days, a substantially increased number of
activated T cells enter the CNS, fostering subsequent T-cell
migration deeper into the CNS parenchyma [19]. They can
now cause tissue destruction leading to, depending on the
model, demyelination and, ultimately, neurologic deficit.
During this phase, microglial cells are thought to provide
additional Ag-specific as well as MHC-independent
signals for invading inflammatory T cells. We propose
that, during both phases, the interactions of auto-reactive
Th cells with CNS resident cells are critical determinants of
disease development. We will focus here on the recent
advances made in understanding the contribution of CNS
resident and associated cells in autoimmune-mediated
tissue injury.
Antigen presentation and T-cell immunity
Antigen presentation is a crucial process during immunity
for the generation of protective T-cell responses against
pathogens or other foreign structures. This requires APCs
capable of engulfing foreign microorganisms and expressing
the antigenic peptides in the major histocompatibility
complex molecules on the cell surface. CD4 T cells
recognize antigens that are associated with the MHC class
II molecules, whereas CD8 T cells bind antigen–MHC class
I complexes. Both naïve CD4 and CD8 T cells become fully
activated only when receiving additional co-stimulatory
signals from the APC, whereas the activation of T cells that
have already been “primed” or exposed to their antigens
may be less dependent on co-stimulation [20, 21]. There are
“professional” APCs equipped to initiate a primary immune
response by the presentation of antigen to naïve T cells and
“non-professional” APCs that can only stimulate a second-
ary response by the presentation of antigen to primed Tcells.
The dendritic cells and macrophages of the immune system
possess the former ability, whereas B cells and certain
stromal cells may engage in secondary T-cell responses [22].
MS and EAE are thought to be mainly mediated by the
actions of myelin-reactive CD4 T cells. This notion is most
strikingly supported by the fact that the adoptive transfer of
myelin-reactive CD4 T lymphocytes into naïve animals can
initiate EAE. The role of CD8 T cells remains controversial
[23, 24], while several groups could clearly demonstrate that
CD8 T cells restricted to an MHC class I myelin antigen can
transfer EAE [25–27]; the lack of CD8 T cells in actively
immunized mice worsens EAE development [28, 29]. For
the purpose of clarity, we will focus on CD4 Tcells, but very
similar rules apply to CD8 T cells.
Most tissues of the body contain APCs, which capture
antigen and migrate to the draining lymph nodes for the
initiation of T-cell activation. Once activated, T cells leave
the lymphoreticular system, and infiltrate and inspect tissues
for foreign antigens that are being displayed on resident
APCs. If T cells were fully activated, they proliferate,
differentiate, and acquire an increased sensitivity to Ag on
restimulation in tissues. The most effective APC of the
systemic immune compartment are DCs. DCs are currently
being heavily investigated as they appear to conduct major
control over the development of immunity. Several distinct
subtypes of DCs have been identified and their distinct
immune function is being investigated. Under steady-state
conditions, DCs constantly capture Ag and present it to T
cells. Under such conditions, DCs do not effectively prime
naïve T cells due to the lack of appropriate secondary
co-stimulatory signals. These “inefficient” T cell/APC en-
counters are likely to mediate peripheral immune tolerance
[30]. The presence of danger signals such as microbial
products, however, leads to DC activation, maturation, and
ultimately licensing such DCs to prime naïve T cells. DC
maturation leads to an arrest of MHC recycling and, hence,
the formation of stable MHC/peptide complexes. Further-
more, DC maturation coincides with an increase in the
expression of co-stimulatory signals required for efficient
priming. We will apply this concept to CNS immunity and
inflammation.
Encephalitogenicity
In addition to T-cell activation and expansion, APCs are also
capable of regulating the differentiation of effector T cells.
During their activation, CD4 T helper (Th) cells can
differentiate into at least two subsets of effector cells: Th1
cells, which secrete predominantly IFNγ and TNFα, and
Th2 cells which secrete IL4, IL5, and IL10. In general, Th1
cells are responsible for eliciting phagocyte-mediated
defense against infections and for promoting the differen-
tiation of CD8 T cells into active killer cells, whereas Th2
cells mediate humoral immune responses by stimulating the
differentiation of B cells and can downregulate Th1
responses. As well as their protective roles in host defense,
Th1 cells were proposed to also mediate organ-specific
autoimmunity and have been implicated in the pathogenesis
of EAE and MS [31]. Th2 cells can conversely suppress
EAE and MS, although they may exacerbate these diseases
in immuno-compromised hosts [32]. Thus, the final
composition of the Th cell response to antigen can determine
whether the outcome of infectious, inflammatory, and
autoimmune responses is beneficial or detrimental. Many
factors influence the development of Th1 or Th2 cells: for
example, the cytokines (e.g., IL12 favors Th1 cells and IL4
favors Th2 cells), the Ag doses, the co-stimulatory
molecules as well as the types of activated APCs. The
Th1/Th2 concept has recently undergone a significant
paradigm shift. This shift was brought about by the
observation that the major Th1 cytokine IFNγ could be
demonstrated to not exacerbate disease development. On the
contrary, lack of IFNγ actually worsens the disease [33] and
even permits disease development in otherwise resistant
mouse strains [34, 35]. In addition, mice lacking the most
critical Th1-inducing cytokine IL12 are also hyper-suscep-
tible to EAE [36–38]. This and a host of additional data
indicate that the Th1/Th2 paradigm does not apply to EAE
but that a discrete population of ThIL17 cells driven by IL23
is important for the development of autoimmune diseases
such as EAE or collagen-induced arthritis [39–41].
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Immune privilege
Immunity is necessary to eliminate dangerous infectious
agents and to support regeneration, but it also causes
significant tissue damage. At sites harboring irreparable
structures such as cornea and lens in the eye or neuronal
networks in the brain, where regeneration for obvious
reasons is limited, a strong evolutionary pressure may have
caused organ-specific modulation of immunity (for a
review, see [5, 42]). The anti-inflammatory environment
of eye and brain became apparent in transplantation studies
[1] and their state of relative tolerance to grafts has been
termed “immunologically privileged” [2]. In the brain,
immune privilege has been attributed to two morphological
peculiarities of this organ, the absence of classical lymph
vessels and the BBB, a mechanical diffusion barrier for
hydrophilic blood molecules built by specialized tight
junctions in brain capillaries [5]). However, antigens turned
out to drain from brain to cervical lymph nodes [6], and
leukocyte recruitment takes place in postcapillary venules
[4]. The picture of the brain being ignored by the immune
system has thus been shifted to a more dynamic scenario, in
which immune tolerance is actively maintained involving
various mechanisms such as peripheral depletion and tight
control over the activation state of local APCs (for a review,
see [42]). The former is achieved by the constitutive
expression of CD95 ligand (FasL and Apo1L) allowing
apoptotic elimination of activated T cells [43–45]. As for the
latter, vasoactive intestinal peptide [46] and transforming
growth factor-beta [47] seem to be key players (for a review,
see [5]). Moreover, a negative feedback mechanism exists
involving the induction of indolamine 2,3-dioxygenase on
microglia through IFNγ secreted by encephalitogenic Th1
cells leading to arrest or apoptosis of T cells [48].
As a consequence of such multilayered tolerance
mechanisms, the CNSmicroenvironment appears inefficient
for an immune-mediated inflammation, a necessary event to
defeat pathogens. From an evolutionary point of view, it
may in fact be less detrimental for the individual to tolerate
certain neurotropic viruses (such as varicella zoster) than the
elimination of all infected neurons [5, 42]. In mice, infection
of peripheral tissues with lymphocytic choriomeningitis
virus (LCMV) usually induces a massive expansion of
virus-specific CD8 T cells, which results in efficient viral
clearance and host survival [49]. When the virus is
inoculated directly to the CNS, however, it causes a lethal
disease. There is unequivocal evidence that the virus-
specific T-cell response is implicated in the fatality of
LCMV infection in the CNS [50, 51]. Should it be infected,
the CNS would appear a defenseless victim, at the mercy of
the peripheral immune system to control or end the attack.
Nevertheless, T cells that control infections of the peripheral
tissue without causing irreparable collateral damage cannot
do so within the brain. This may be attributed to the simple
fact that lost neurons can hardly be replaced and, therefore,
dealing with viral infections in the brain is impossible
without causing permanent or even lethal cell loss. How-
ever, a recent study in which patients were treated with a
mAb against VLA4 demonstrates that restricting the CNS’
immune surveillance (Fig. 2) could potentially lead to out-
of-control expansion of pathogens such as the normally
well-controlled JC virus (human polyoma virus) [52]. Under
pathologic conditions, the action of CNS-associated APCs is
absolutely essential for the immune invasion of the CNS.
This also suggests that permanent elimination of infectious
agents may take place within the brain in the absence of
significant clinical symptoms.
MHC and co-stimulatory molecules are indeed strongly
upregulated in CNS infections and in virtually all other
CNS pathologies, including ischemia, axonal degeneration,
neoplasm, traumatic nerve injury, and neurodegenerative
disorders, such as multiple sclerosis, HIV-associated
dementia, and Alzheimer’s, Parkinson’s, and Creutzfedt–
Jakob’s disease [53–59]. Why and how such immune-
associated reactivity occurs in the disturbed CNS remains
speculative; such reactivity may reflect an attempt of the
CNS to defend and repair. For example, CD4 T cells are
recruited to sites of myelinated axon injury [60], and they
promote regeneration of neurons via secretion of nerve
growth factors after in situ antigen-specific activation
[61–63], but secondary damage has also been reported
[64, 65]. In MS, immune reactivity in the CNS also
becomes destructive. CD4 T cells are blamed for wrongly
attacking CNS myelin through secretion of pro-inflamma-
tory cytokines and activation of cytopathic factors and
cytotoxic CD8 T cells [31, 66, 67].
All of these examples clearly show that immunity within
the CNS does occur and emphasize the delicate balance of
Fig. 2 There is vivid immune surveillance in perivascular spaces, as
activated T cells pass the vessel wall of postcapillary venules even
under apparently physiologic conditions. However, progression into
the neuropil appears to depend on antigen recognition and re-
stimulation by antigen-presenting (dendritic) cells located in
Virchow–Robin spaces [17]. This reconfirmation and target recog-
nition event apparently enables T lymphocytes to pass the glia
limitans and to enter the brain parenchyma, where they can interact
with microglial cells which drive the inflammatory cascade leading
to tissue damage [99]. In the absence of APCs presenting the
cognate antigen, T cells do not proceed across the glia limitans.
They may either recirculate or undergo apoptosis
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costs over benefits during neuroinflammation. In the
following, we will focus on the key question, where and
how antigens are presented within the CNS.
Antigen presentation and target recognition in EAE
In EAE and ADEM, the priming phase occurs within the
systemic immune compartment. After immunization-in-
duced expansion of neuroantigen-restricted encephalitogen-
ic Th cells, these T cells are now equipped to leave the
lymphoreticular environment and invade the bodies’ tissues
scanning for APCs presenting their cognate Ag. Oligoden-
drocytes are ultimately the target of such Th cells in the case
of myelin Ag immunization. They are the CNS’myelinating
cells wrapping their cell membranes around axons to
provide nerve insulation for optimal conductivity. However,
while oligodendrocyte loss and demyelination are ultimately
seen in EAE, oligodendrocytes cannot be directly recog-
nized by CNS-invading T cells as they are incapable of
expressing MHC class II molecules [68]. A compulsory
third party APC is an absolute requirement for encephali-
togenic Th cells to even recognize myelin Ag within the
CNS.
Ag presentation likely occurs at the level of the BBB
promoting entry of T cells into the CNS. Cerebral micro-
vascular endothelial cells have been considered as APCs
because of their large cumulative surface and their unique
anatomical location between circulating T cells and the
extra-vascular sites of antigen exposure. However, endo-
thelial cells, unlike perivascular APCs, do not constitutively
express MHC class II molecules in vivo or in vitro [69]. In
two different models of antigen presentation, brain endo-
thelial cells have failed to induce T-cell proliferation [69, 70,
71]. No data has causally implicated endothelial expression
of class II MHC as an important element in disease.
Oligodendrocytes are the apparent target of the autoim-
mune attack in MS and EAE. It is feasible that MS is in
contrast to EAE, a primary degenerative disease in which
oligodendrocytes undergo premature death resulting in
subsequent immune activation [72]. However, the data
supporting this hypothesis are not numerous. In contrast,
there is overwhelming evidence that immune cells from the
systemic immune compartment become activated and that
myelin-reactive lymphocytes are the prime and initial
mediators of the disease. This is certainly the case in EAE,
where immune tolerance to self (myelin) is broken
resulting in the expansion of myelin-reactive T cells
which subsequently migrate into the CNS to initiate an
inflammatory cascade leading to demyelination, oligoden-
drocyte loss, and axonal degeneration. However, viewing
the CNS only as the defenseless target of such an immune
assault would be oversimplistic. There is now clear
evidence that CNS-associated DCs play a vital role in
target recognition for neuroantigen-reactive T cells and that
CNS resident microglia are crucial for the maintenance of
encephalitogenicity during an immune response. We will
now discuss the different anatomic locations and cellular
compositions of potential encounters between encephali-
togenic T cells and their APCs.
Microglia, sentinels of the CNS parenchyma
Glial cells were initially defined as the glue (Greek: glia)
keeping the neurons in the brain together [59]. Astroglia as
well as oligodendroglia clearly have a supporting function
for neuronal development, sprouting, and activity. In 1932,
the neuropathologist del Rio-Hortega described a third type
of glial cell, later named microglia [73]. Microglia
comprise about 10% of the total glial population in the
CNS parenchyma [59] and are in contrast to the other cells
residing in the CNS parenchyma not of neuroectodermal
but of mesodermic origin. While the origin of microglia has
long been disputed, it has become definitively established
that they are of hematopoietic origin. They share many
properties with macrophages, having developed from a
common precursor cell [74, 75]. The most widely held
hypothesis is that, early in fetal development, myeloid cells
infiltrate the CNS and develop into parenchymal microglia
[76]. Unlike the CNS-associated phagocytes of the lepto-
meninges and the perivascular spaces, microglia are not
readily repopulated by bone-marrow-derived monocytes
during adulthood [77], but there is evidence for regional
turnover at low rates and rapid transformation of blood
monocytes into microglia during pathologies [5, 78].
Under virtually all inflammatory conditions in the CNS,
parenchymal microglial cells rapidly upregulate MHC
class II expression, suggesting that they may participate in
Ag presentation that occurs during the inflammatory
process [57, 75, 79, 80, 81]. Activated microglia also
upregulate co-stimulatory molecules such as CD40, CD80,
and CD86, which equip them for Ag presentation to T cells
[16, 55, 70, 82].
Microglia, like the CNS-associated cells, phagocytose
myelin [83–85], indicating that these cells can activate
myelin-specific CD4 T cells. Microglia infected with
Theiler’s murine encephalomyelitis virus have been dem-
onstrated to be activated to efficiently process and present
not only endogenous viral epitopes but also exogenous
myelin epitopes to CD4 T cells [86]. Human microglia,
either immediately ex vivo or cultured for several days,
have been reported to act as APCs and to induce both
primary and secondary proliferative T-cell responses
[79, 87]. A similar APC potential was also demonstrated
for rat microglia isolated from neonatal brains [18, 88], but
in these studies with neonatal glial cultures, extraneural,
leptomeningeal, and perivascular CNS-associated APCs
were not separated from microglia and may contribute to
T-cell activation. Furthermore, recent reports have raised
the concern on whether such neonatally derived cells
faithfully represent the adult population in vivo. In fact,
microglia isolated from adult mice fail to present antigen to
naïve antigen-specific CD4 T cells [89], but those that are
pretreated with IFNγ or isolated from mice with EAE can
activate T cell lines in an antigen- and CD86-dependent
manner in vitro [90]. Nevertheless, adult rodent microglia
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may not support a typical T-cell activation: T cells become
blasts, express activation markers CD25 (IL2 receptor
alpha chain) and CD134, and produce the cytokines TNFα
and IFNγ, in an antigen-specific manner, but do not
proliferate [7, 91, 92]. Even when MHC class II expression
is enhanced by the induction of systemic graft vs host
disease, the isolated microglia still do not promote
proliferation of T cells but rather induce death of these
cells through apoptotic mechanisms [91]. In line with this
finding, many T cells in the CNS of rodents with EAE
undergo apoptosis within the parenchyma [93], where they
are in contact with microglia. There is now overwhelming
evidence that microglia do not serve as initial APCs to
invading myelin-reactive T cells [16, 17].
The activation and differentiation of CD4 T cells require
MHC class II recognition and co-stimulation. Studies using
adoptive transfer of primed myelin-reactive CD4 T cells
into mice in which APCs can no longer deliver a specific
co-stimulatory signal have identified CD40, CD80/CD86
(B7), and CD134 (OX40) as important for the reactivation
of these T cells in the CNS [94, 95]. The observation that
microglia are largely resistant to radiation while CNS-
associated cells are radiation sensitive has allowed the
generation of radiation bone marrow chimeric mice to
further pinpoint on the most important source of these co-
stimulatory molecules in the CNS in an in vivo setting.
Recent work using such an approach to create bone marrow
chimeric mice in which CD40 is deficient only in microglia
but is intact in CNS-associated cells has revealed that
microglial CD40 is most critical to the reactivation of
peripherally primed encephalitogenic T cells for the
production of Th1 cytokines and chemokines, the recruit-
ment of leukocytes to the CNS parenchyma, and the
progression of EAE [96]. Like murine microglia, human
microglia can express CD40 and, in response to CD40
stimulation, produce IL12 [82, 87]. IL12 is a 70-kDa
heterodimeric, secreted protein consisting of two disulfide-
linked subunits, p35 and p40. The p40 subunit can also
associate with a different p19 subunit to form IL23, which
has recently been shown to be essential in the activation of
the CNS-associated macrophages for autoimmune inflam-
mation in the mouse brain [36, 37, 97]. This study and
others [38, 98] have challenged the view that IL12 is
central in autoimmune inflammation of the CNS. Though
both microglia and CNS-associated macrophages can
produce IL23, only macrophages can respond to this
cytokine [37]. Lastly, it was shown by Heppner et al. that
EAE was considerably repressed in mice in which
microglial cells were transiently “paralyzed”. The inhibited
activation of microglia leads to a reduced inflammation of
the CNS, suggesting that the release of reactive oxygen
species intermediates in addition to cytokines and chemo-
kines by activated microglial cells is crucial for the
development and maintenance of EAE [99]. These
observations collectively allow us to speculate that the
interplay between microglia and macrophages via IL23
may regulate CNS inflammation triggered by primed
autoimmune CD4 T cells. Infiltrating T cells expressing
CD40 ligand (CD154) can stimulate microglial CD40 to
upregulate IL23. This cytokine in turn can directly act on
memory T cells [100] and activates CNS-associated
macrophages to produce critical inflammatory cytokines
(e.g., IL-17) and possibly other co-stimulatory molecules
(e.g., CD80/CD86 and CD134). A better understanding of
the molecular mechanisms regulating the expression of
CD40 and its ligand in the CNS will undoubtedly cast new
light on the functions of these co-stimulatory molecules
beyond T-cell activation.
It remained unresolved whether microglia actually
present antigen to naïve Tcells in vivo during inflammation
until recently. It is likely that T-cell activation and
expansion are subjected to a tighter regulation in the
CNS parenchyma than elsewhere. CNS APCs were indeed
found to inhibit T-cell proliferation through the release of
toxic levels of nitric oxide [92] and to induce T cell
apoptosis through Fas–Fas ligand interaction [7, 91]. For a
long time, microglia have appeared to be the most capable
APCs to initiate and sustain a T-cell-mediated immune
response within the CNS [101]. By combining bone
marrow chimerism and gene targeting, we restricted the
APC capability to either the CNS parenchyma (microglia)
or the systemic immune compartment. Upon transfer of
MOG-reactive T cells, chimeras with MHC class II
expression restricted to the systemic immune compartment
and CNS-associated cells were susceptible to EAE.
However, mice with MHCII expression restricted to the
CNS parenchyma were resistant to the development of
disease [17]. Taken together, these findings provide
evidence that cells within the CNS parenchyma such as
microglia do not serve as APCs permitting lymphocyte
entry. However, for the development of CNS inflammation
and the effector phase during EAE, microglia are pivotal
components. We will later discuss that the CNS-associated
and not CNS residents permit the recognition of the
cognate neuroantigen by CNS-invading T cells.
Astrocytes
While numerous studies have supported the role of
microglia in T-cell activation within the CNS, whether
astrocytes, the major glial populations, also play such a role
is a lively controversy [102–105]. On one hand, both in situ
and in vivo evidence indicate that astrocytes express high
levels of MHC class II and co-stimulatory molecules
(e.g., CD80, CD86, CD40, ICAM-1, and VCAM-1) upon
exposure to IFNγ [106] and are capable of sensing
pathogens through toll-like receptors [107]. It is interesting
to note that CD80 and CD86 are differentially regulated on
astrocytes during the course of EAE: CD86 is upregulated
at the peak disease, while CD80 dominates during
remission [108]. Furthermore, astrocytes express elements
involved in the MHC class II endocytic pathway and are
capable of processing native MBP for presentation to
myelin-specific T cells in vitro [109]. Myelin-specific
T cells that were activated by astrocytes in vitro were
indeed able to transfer EAE in SJL/J mice [110]. Although
both untreated and IFNγ-treated astrocytes can initiate
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secondary T-cell responses, only treated astrocytes activate
naïve T cells [106]. However, many other studies do not
support astrocytes as efficient APCs [18, 111, 112]. It is
interesting that astrocyte-derived soluble factors suppress
LPS induction of co-stimulatory molecules on microglia
and macrophages [47], suggesting that astrocytes are not
only themselves poor stimulators of CD4 T cells but can
also inactivate other APCs.
Unlike microglia, astrocytes may require additional
stimuli in combination with IFNγ to provide stronger
synergistic activation of their APC function [113]. Because
of their phenotypic and functional heterogeneity, astrocytes
may differ in their APC function, and this may add to the
controversy. Moreover, strain differences might influence
the antigen-presenting potential of astrocytes. Upon in
vitro stimulation with IFNγ, astrocytes that were isolated
from EAE-susceptible Lewis rats, but not from EAE-
resistant Brown Norway rats, expressed higher levels of
MHC class II and induced proliferation of myelin-specific
T cell lines [114]. A similar correlation between EAE
susceptibility and astroglial MHC class II induction was
also observed for certain mouse strains [115].
CNS-associated cells, sentinels at the gateway
to the CNS
Compartments in association to the CNS, such as the
Virchow–Robin’s (perivascular) space, the leptomeninges,
and the choroid plexus, contain phagocytes that have been
identified as macrophages and dendritic cells, based on
molecular and functional phenotypes [116, 117]. They are
continuously replenished by bone-marrow-derived mono-
cytes [77, 118]. Their normal turnover may be indeed
exploited by pathogens, such as lentiviruses, to enter the
CNS [117]. Under various pathological conditions, these
CNS-associated cells can increase in number transiently or
for longer periods [119]. Like peripheral macrophages,
they constitutively express high levels of MHC class II,
CD11b, and the leukocyte common antigen CD45, which
distinguish them from the CD45low parenchymal microglia
[79, 120]. Both in vitro and in vivo studies strongly point to
the CNS-associated cells, rather than the microglia, as
competent APCs. When isolated from adult rodent CNS,
they were found to activate both naïve and primed CD4 T
cells, as efficiently as splenic or lymph node APCs, and
even more so than CD45low parenchymal microglia
isolated from the same animals [7, 91, 121]. In vivo
studies using infectious or autoimmune models also
support the immune functions of the CNS-associated
cells. For instance, Matyszak and Perry showed that an
injection of the pathogen Bacillus Calmette–Guerin (BCG)
to the meninges provokes a typical inflammation and a
BCG antigen-specific T-cell response, as seen in the skin
after a subcutaneous challenge [122]. By contrast, no such
immune response was observed when the pathogen was
delivered directly to the CNS parenchyma. Using different
MHC-class-II-restricting T-cell elements, Hickey and
Kimura could show that perivascular APCs “considered
to be macrophages” are sufficient to provide stimulatory
signals for T cells to infiltrate the CNS. However, to induce
EAE, the rats were required to develop graft vs host disease
[123] and thus changing the inflammatory environment
and infiltrates of the CNS.
Due to the strategically important location, between the
outermost basal lamina of the vessel wall endothelium and
the one on top of the glia limitans CNS parenchyma,
perivascular CNS-associated APCs are ideal candidates to
present Ag to invading myelin-reactive T cells. These
CNS-associated cells may engage in de novo processing of
myelin antigen for in situ activation or tolerance induction
of effector/memory as well as naïve T cells. They also seem
strategically positioned for influencing T-cell trafficking to
the CNS parenchyma. When their function is perturbed or
absent, lymphocyte migration into the CNS parenchyma is
blocked and EAE is prevented [124]. In fact, antigen
recognition in perivascular spaces was proposed to be
required for T cells to progress from the Virchow–Robin
space across the glia limitans into the neuropil [125]. CNS-
associated cells have been shown recently to be important
sources of TNFα, which induces glial production
of chemokines, such as TCA3 and MCP, to mediate
leukocyte recruitment and initiation of inflammation in the
parenchyma [126].
Using transgenic mice in which MHC class II is
exclusively targeted to DCs, we showed that DCs alone
are sufficient to present the cognate antigen to MOG-
reactive T cell and are permissive for the development of
CNS inflammation [17]. Furthermore, by augmenting the
number of CNS-associated DCs, upon adoptive transfer
with MOG-reactive T cells, the disease severity of EAE is
increased. In MS lesions, analogous cells, CD209+ DCs,
were detected to be associated with vessels and in close
proximity to invading T cells. These data indicate that
CNS-associated DCs are the crucial APCs in conferring
CNS inflammation of encephalitogenic T cells [17].
In agreement with these results, McMahon et al.
demonstrated in two mouse models of EAE that epitope
spreading occurs directly in the CNS and not in peripheral
lymphoid tissues. They showed that DCs were the most
crucial APC population of the CNS, initiating epitope
spreading in the inflamed CNS [16]. Neither microglia nor
macrophages isolated form the CNS were capable of
stimulating naive myelin-specific T cells. These in vivo
studies collectively strongly suggest that CNS-associated
DCs are capable of initiating both primary and secondary
T-cell responses locally. These CNS-associated APCs, like
certain antigens in the brain, may drain to lymphoid organs
to activate naïve T cells. The outflow of the normal brain
can escape to the interstitial and cerebrospinal fluids, which
follow cranial nerves to drain into nasal lymphatics and
cervical lymph nodes or can drain to the spleen via blood.
Studies tracing these outflow pathways have revealed that,
contrary to the earlier view, both intracranially injected
macrophages and antigens drain preferentially to the
cervical lymph nodes [127–129]. Myelin basic proteins
were indeed elevated in the cerebrospinal fluid of patients
with relapsing–remitting MS [130] and myelin-ingested
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APCs were also abundant in their cervical lymph nodes
[128]. In addition, the cervical lymph nodes of marmoset
and rhesus monkeys that were immunized with only myelin
oligodendrocyte glycoprotein contained an accumulation
of APCs that had engulfed other myelin antigens, such as
myelin basic protein and proteolipid protein [128]. These
observations indicate that myelin antigens must have
drained or that APCs containing them must have migrated
to the cervical lymph nodes from the inflamed CNS.
However, it is unclear whether myelin antigen presenta-
tions in the cervical lymph nodes would result in the
progression or modulation of immune responses in the
CNS. In support of the cervical lymph node implication in
disease, encephalitogenic T cells primed in these lymph
nodes were found to preferentially target the brain [131]
and an ablation of the cervical lymph nodes markedly
attenuated the cryolesion-enhanced EAE in Lewis rats
[132]. Although the drainage of CNS-derived antigens into
the cervical lymph nodes generates local production of
antigen-specific antibodies, it does not provoke a rapid
destruction of the CNS [127]. Moreover, intracranially
injected antigens in normal mice rather evoked a systemic
immune deviation that suppresses normal T-cell effector
activity [133]. Cervical lymph node cells from the
protected mice were able to transfer such suppression to
naïve recipients. However, alymphoplasia mice, which
completely lack all lymph nodes, are fully susceptible to
EAE induced by an adoptive transfer of MOG-reactive T
cells, indicating that the presence of CNS antigen in the
cervical lymph node is a result of CNS inflammation but
not a driving force [17].
Concluding remarks
Immunization of naïve mice with myelin Ags results in the
expansion of potentially pathogenic/encephalitogenic T
cells. Immunization-induced expansion likely occurs within
secondary lymphoid tissues, although recent data from our
laboratory indicate that immunization-induced T-cell prim-
ing can occur outside of such dedicated structures (manu-
script in preparation). Upon activation and maturation,
myelin-reactive T cells migrate through the body’s tissues in
search of their cognate antigen. In perivascular spaces, T
cells apparently re-encounter their cognate antigen presented
by DCs, leading to reactivation enabling the T cells to cross
the glia limitans and to invade the CNS parenchyma. This
confirmation event is vital, as the encounter between
encephalitogenic T cells and MHC-class-II-expressing
DCs is an absolute requirement for disease development.
T cells which recognize non-myelin Ags can also travel into
this location but will not receive their reconfirmation signal
[134]. After this second encounter with their cognate Ag, T
cells cross the glia limitans and migrate deeper into the CNS
parenchyma where they can activate CNS resident micro-
glia. They in turn will produce a host of vasoactive
substances, cytokines, and chemokines, leading to the
invasion of other leukocytes such as poly- and mono-
morphonucleated phagocytes. The presence of such inflam-
matory mediators including IL23 ultimately leads to the
development of a tissue lesion. While the precise factors that
lead to the collateral tissue damage of myelinating tissue
remain to be definitively established, our current knowledge
on target recognition and the location of vital T cell/APC
interactions could lead to the development of novel
therapeutic strategies for the treatment of inflammatory
CNS diseases.
Under steady-state and physiologic conditions, the
CNS-associated APCs are likely to be vital for the
maintenance of peripheral tolerance. Immune surveillance
of the CNS under non-pathologic conditions appears to be
essential for the control of CNS pathogens. The goal now
would be to use this knowledge and to target these APCs to
reestablish peripheral immune tolerance against self and to
use this approach as a therapeutic strategy for the treatment
of neuroimmune disorders.
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